Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28503073 | 0.98 | KDM4E (0.44) | KDM4EALDH1A1USP2HSP90AB1GAA | |
| Hydrochloric Acid SCHEMBL44961 | 0.98 | KDM4E (0.44) | KDM4EALDH1A1USP2HSP90AB1GAA | |
| SCHEMBL1441637 | 0.82 | KMT2A (0.44) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL1039137 | 0.82 | TSHR (0.40) | KDM4EALDH1A1MAPTKMT2AMAPK1 | |
| SCHEMBL27456186 | 0.82 | KDM4E (0.32) | KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1039136 | 0.81 | TSHR (0.39) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL9515698 | 0.81 | L3MBTL1 (0.36) | KDM4EALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL3002697 | 0.81 | TSHR (0.45) | KDM4EALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL23542511 | 0.80 | TP53 (0.31) | KDM4ETP53 | |
| SCHEMBL13262678 | 0.80 | TSHR (0.44) | ALDH1A1MAPTKMT2ASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250076302-A1 | DETECTING THE PRESENCE OF URINARY STONE DISEASE USING A PLURALITY OF URINARY METABOLITES | THE CLEVELAND CLINIC FOUNDATION | 2025-03-06 | — | — | US | disclosed |
| US-20240360121-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-10-31 | — | — | US | disclosed |
| CN-118638140-A | Oxo-substituted compounds | 住友制药株式会社 | 2024-09-13 | — | — | CN | disclosed |
| CN-112135830-B | Oxo-substituted compounds | 住友制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| US-11958849-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-16 | — | — | US | disclosed |
| US-11713313-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713313-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713313-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230124815-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-20 | — | — | US | disclosed |
| US-20230124815-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-20 | — | — | US | disclosed |
| EP-1020453-A1 | 6,7-ASYMMETRICALLY DISUBSTITUTED QUINOXALINECARBOXYLIC ACID DERI VATIVES, ADDITION SALTS THEREOF, AND PROCESSES FOR THE PREPARATION OF BOTH | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |
| WO-2000039130-A2 | PRENYL TRANSFERASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2000-07-06 | — | — | WO | disclosed |
| EP-0980366-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0980366-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-02-23 | — | — | EP | disclosed |
| WO-1999012912-A1 | THIOUREA DERIVATIVES OR NON-TOXIC SALTS THEREOF FOR INHIBITNG RAS-TRANSFORMED CELL GROWTH | YUHAN CORPORATION (KR) | 1999-03-18 | — | — | WO | disclosed |
| EP-0891352-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1998049160-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1997036891-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| EP-0783517-A2 | THIOL-FREE INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010034-A2 | THIOL-FREE INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360121-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | KDM4E 3347/4885ALDH1A1 882/4885USP2 2989/4885 |
| US-20230124815-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | KDM4E 3347/4885ALDH1A1 882/4885USP2 2989/4885 |
| US-11958849-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLG1 | KDM4E 3347/4885ALDH1A1 882/4885USP2 2989/4885 |
| US-11713313-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLG1 | KDM4E 3347/4885ALDH1A1 882/4885USP2 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.